摘要
目的:探讨补肾抗衰片干预不稳定型心绞痛(UAP)的临床疗效及其对血清炎症介质水平的影响。方法:将60例UAP患者随机分为治疗组及对照组,各30例。对照组行西医常规治疗,治疗组在西医常规治疗基础上加服补肾抗衰片。观察两组患者治疗前后心绞痛症状积分、疗效、心绞痛发作情况及全球急性冠脉综合征注册(GRACE)风险评分,并检测两组患者血清干扰素-γ(INF-γ),白细胞介素(IL)-2,肿瘤坏死因子-α(TNF-α),IL-4水平的变化。结果:与治疗前比较,两组患者治疗后心绞痛症状积分及发作情况均好转(P<0.05,P<0.01),血清致炎因子水平均明显下降(P<0.05),且治疗组的疗效明显优于对照组(P<0.05)。GRACE风险评分与患者肾虚证积分具有高度相关性。结论:补肾抗衰片联合西医常规治疗干预UAP疗效确切,可改善患者临床症状,改善血清Th1/Th2漂移。
Objective: To investigate the clinical efficacy of Bushen Kangshuai (BSKS) tablets for unstable angina pectoris (UAP) and observe its effect on flammatory mediator levels in serum. Method: Sixty UAP patients were randomly assigned to treatment group (30 cases) and control group (30 cases). Patients in control group received routine western medical treatment, while those in treatment group additionally took BSKS tablets. The angina symptom scores, clinical efficacy, angina frequencies, and Global Registry of Acute Coronary Events (GRACE) risk scores were compared between two groups both before and after treatment. The changes in interferon-γ (IFN-γ) , interleukin (IL)-2, tumor necrosis factor-α (TNF-α), and IL-4 levels in serum were detected in both groups by enzyme-linked immunosorbent assay. Result: The angina symptom scores and angina frequency and duration were improved in both groups after treatment (P 〈 0.05, P 〈 0.01 ) , and the flammatory mediator levels in serum were significantly reduced in both groups (P 〈 0.05 ) , the clinical efficacy in treatment group was significantly superior to that in control group (P 〈 0.05 ). GRACE risk scores were highly correlated with the kidney deficiency syndrome scores of patients. Conclusion: Bushen Kangshuai tablet combined with routine western medicine treatment is an effective way to improve the clinical symptoms and lower the levels of inflammatory mediator in patients with UAP.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2016年第14期171-176,共6页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金项目(81173244)